Bexlosteride
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | LY 300502 |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H16ClNO |
Molar mass | 249.74 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride.[1][2] It is selective for the type I isoform of the enzyme.[1] It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.[3][4]
See also
[edit]References
[edit]- ^ a b Chang C (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
- ^ Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- ^ "Drug Profile: Bexlosteride". Adis Insight.
- ^ Reaxys entry for bexlosteride: Reaxys Registry Number: 6635310
Drugs used in benign prostatic hyperplasia (G04C) | |
---|---|
5α-Reductase inhibitors | |
Alpha-1 blockers | |
Steroidal antiandrogens | |
Herbal products | |
Others |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields